Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRCT response to glucocorticoid induction therapy in pulmonary sarcoidosis
NL-OMON48613Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of prednisone and prednisolone in pulmonary sarcoidosis and sarcoidosis, sponsored by Celgene Corporation. Primary endpoints: Change from baseline in HRCT-based lobar volumes at FRC and TLC and Change from baseline in HRCT-based airway wall volume. Started Oct 2018; status: active, not recruiting.
02
Drugs
prednisoneprednisolone
03
Conditions
pulmonary sarcoidosissarcoidosis
Beyond the preview
Go deeper on NL-OMON48613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48613.